Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AzentaSTU:BA3 -1.40%78 Debt-to-Equity is 0.04 as of Jun. 2026, which is at its 10-year median of 0.04. GuruFocus rates STU:BA3 with a GF Score™ of 78/100 and a GF Value™ of €45.97 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 697 Medical Devices & Instruments companies, Azenta ranks better than 85.94% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Azenta's Debt-to-Equity or its related term are showing as below:
STU:BA3'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.04 Max: 0.75
Current: 0.04
During the past 13 years, the highest Debt-to-Equity Ratio of Azenta was 0.75. The lowest was 0.01. And the median was 0.04.
STU:BA3's Debt-to-Equity is ranked better than 85.94% of 697
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs STU:BA3: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Azenta Debt-to-Equity Related Terms
Azenta Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Azenta's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:BA3 vs KMTS, STAA, BLFS: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Azenta's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Azenta Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Azenta's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Azenta's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Azenta (STU:BA3) has a Debt-to-Equity of 0.04 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Azenta and its competitors. This is near median its historical median of 0.04. Over the past decade, Azenta's Debt-to-Equity has ranged from 0.01 to 0.75. According to the industry distribution chart, Azenta ranks #98 out of 697 companies in the Medical Devices & Instruments industry, placing it in the top 14.1%.
Is Azenta's Debt-to-Equity too high?
Azenta's current Debt-to-Equity of 0.04 is near median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.75. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Azenta's value of 0.04 is 82.6% below this industry median. Based on the distribution chart, Azenta ranks #98 out of 697 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Azenta has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Azenta's Debt-to-Equity compare to KMTS and STAA?
According to the Medical Devices & Instruments industry distribution chart, Azenta ranks #98 out of 697 companies for Debt-to-Equity. This places Azenta in the top 14% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Azenta's value of 0.04 is 82.6% below this benchmark. Historically, Azenta's own Debt-to-Equity has ranged from 0.01 to 0.75 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.23, Azenta has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Azenta's current Debt-to-Equity of 0.04 is 82.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Azenta and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Azenta's current Debt-to-Equity is 0.04, which is near median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Azenta stock overvalued right now?
Based on GuruFocus' analysis, Azenta (STU:BA3) is currently considered Significantly Undervalued. The stock's GF Value™ is €45.97, compared to a current price of €28.20 — trading 38.7% below its estimated fair value. The current Debt-to-Equity is 0.04, which is near median its 10-year median of 0.04 and 82.6% below the Medical Devices & Instruments industry median of 0.23. Azenta's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Azenta (STU:BA3), the current Debt-to-Equity is 0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Azenta (STU:BA3) Overvalued in 2026?
Based on GuruFocus' analysis, Azenta stock appears to be undervalued.
The current stock price of €28.20 is trading 38.7% below its estimated GF Value™ of €45.97.
GuruFocus considers Azenta to be Significantly Undervalued.
Key valuation signals for STU:BA3:
Debt-to-Equity: 0.04 (near median its 10-year median of 0.04)
GF Value™: €45.97 vs. price of €28.20 (38.7% below fair value)
Industry Position: 82.6% below the Medical Devices & Instruments median (#98 of 697)
No single metric tells the full story. See the STU:BA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
78GF Score
Get the complete analysis for STU:BA3
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:BA3 has been successfully added to your 
